Effect of Insulin Analogs on the Decline of Hemoglobin in Diabetic Patients with Nephropathy

Abstract

Aim: Decrease of hemoglobin occurs in diabetic patients with nephropathy earlier than in nondiabetic patients, probably due to impaired synthesis of erythropoietin (EPO). Apart from EPO, insulin also stimulates erythropoiesis. We investigate whether there are differences between human insulin and insulin analogs in respect of their erythropoiesis stimulating effect.

Patients and Methods: Hemoglobin concentration and other factors which may influence hemoglobin levels were analyzed retrospectively in 203 type 1 diabetic patients with various degrees of kidney function. Eighty-six patients were treated with human insulin and 117 patients received an insulin analog.

Results: Hemoglobin concentration did not differ in patients with normal renal function (creatinine clearance (CCL) >90 ml/min) treated with human insulin or insulin analogs. In patients with impaired renal function (CCL<90 ml/min) there was a significant decrease of hemoglobin with declining kidney function in patients treated with human insulin (r=0.463; p<0.003) but not in patients treated with insulin analog (r=−0.12; p=0.4). This result remained significant after adjustement of multiple potential confounders such as age, gender, diabetes duration, BMI, metabolic control, kidney function, chronic inflammation or use of ACE-inhibitors or AT1-blockers.

Conclusion: Insulin analogs mitigate the decline of hemoglobin in diabetic patients with impaired renal function. This might be due to a stimulating effect of insulin analogs on erythropoiesis via IGF receptor or a sustained activation of the insulin receptor.

Key words

diabetic nephropathy - hemoglobin - human insulin - insulin analogs

References

• 1 Aoki I, Taniyama M, Toyama K. et al . Stimulatory effect of human insulin on erythroid progenitors (CFU-E and BFU-E) in human CD34+ separated bone marrow cells and the relationship between insulin and erythropoietin.  STEM CELLS. 1994;  12 329-338
• 2 Barbieri M, Ragno E, Benvenuti E. et al . New aspects of the insulin resistance syndrome: Impact on haematological parameters.  Diabetologia. 2001;  44 1232-1237
• 3 Bersch N, Groopman JE, Golde DW. Natural and biosynthetic insulin stimulates the growth of human erythroid progenitors in vitro.  J Clin Endocrinol Metab. 1982;  55 1209-1211
• 4 Bosmann DR, Winkler AS, Marsden JT. et al . Anaemia with erythropoietin deficiency occurs early in diabetic nephropathy.  Diab Care. 2002;  24 495-499
• 5 Boyer SH, Bishop TR, Rogers OC. et al . Roles of erythropoietin, insulin-like growth factor 1, and unidentified serum factors in promoting maturation of purified murine erythroid colony-forming units.  Blood. 1992;  80 2503-2512
• 6 Dainiak N, Kreczko S. Interactions of insulin, insulinlike growth factor II, and platelet-derived growth factor in erythropoietic culture.  J Clin Invest. 1985;  76 1237-1242
• 7 Drüeke T, Locatelli F, Clyne N. et al . Normalization of hemoglobin level in patients with chronic kidney disease and anemia.  N Engl J Med. 2006;  355 2071-2084
• 8 Eckardt KU. Cardiovascular consequences of renal anaemia and erythropoietin therapy.  Nephrol Dial Transplant. 1999;  14 1317-1323
• 9 Eckhardt K, May C, Koenen M. et al . IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts.  Diabetologia. 2007;  2534-2543
• 10 Ginsberg BH, Brown TJ. Regulation of insulin receptors in erythroid cells.  Metabolism: clinical and experimental. 1982;  31 728-732
• 11 Hansen BF, Danielsen GM, Drejer K. et al . Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency.  Biochem J. 1996;  315 271-279
• 12 Keane WF, Lyle PA. Reduction of end points in NIDDM with the Angiotensin II Receptor Antagonist Losartan study. Recent advances in management of type 2 diabetes and nephropathy: Lessons from the RENAAL study.  Am J Kidney Dis. 2003;  41 22-25
• 13 Kurtzhals P, Schäffer L, SØrensen A. et al . Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.  Diabetes. 2000;  49 999-1005
• 14 Miyagawa SI, Kobayashi M, Konishi N. et al . Insulin and insulin-like growth factor I support the proliferation of erythroid progenitor cells in bone marrow through the sharing of receptors.  Brit. J Haemat. 2000;  109 555-562
• 15 Nilsson-Ehle H, Bengtsson BA, Lindstedt G. et al . Insulin-like growth factor-1 is a predictor of blood haemoglobin concentration in 70-year-old subjects.  Eur J Haematol. 2005;  111-116
• 16 Quin JD, Miell JP, Smith K. et al . Effect of insulin-like growth factor-I therapy on erythorpoetin concentrations in extreme isulin resistance.  Diabetologia. 1994;  439-442
• 17 Ratajczak J, Zhang Q, Pertusini E. et al . The role of insulin (INS) and insulin-like growth factor-I (IGF-I) in regulating human erythropoiesis. Studies in vitro under serum-fee conditions – comparison to other cytokines and growth factors.  Leukemia. 1998;  12 371-381
• 18 Ritz E, Laville M, Bilous RW. et al . Target Level for haemoglobin correction in patients with diabetes and CKD: Primary results of the anemia correction in diabetes (ACORD) study.  Am J Kid Dis. 2007;  194-207
• 19 Sawada K, Krantz SB, Dessypris EN. et al . Human colony-forming units erythroid do not require accessory cells but do require direct interaction with insulin like growth factor 1 and/or insulin for erythroid development.  J Clin Invest. 1989;  83 1701-1709
• 20 Shand BI, Bailey RR, Lynn KL. et al . Effect of enalapril on erythrocytosis in hypertensive patients with renal disease.  Blood press. 1995;  4 238-240
• 21 Shih LY, Huang JY, Lee CT. Insulin-like growth factor I plays a role in regulating erythropoiesis in patients with end-stage renal disease and erythrocytosis.  J A S N. 1999;  10 315-322
• 22 Singh AK, Szczech L, Tang KL. et al . Correction of anemia with Epoetin Alfa in chronic kidney disease.  N Engl Med. 2006;  2085-2098
• 23 Slieker LJ, Brooke GS, Di Marchi RD. et al . Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor.  Diabetologia. 1997;  40 54-61
• 24 Sohmiya M, Ishikawa K, Kato Y. Stimulation of erythropoietin secretion by continiuous subcutanous infusion of recombinant human GH in anemic patients with chronic renal failure.  Eur J Endocrinology. 2005;  199-207
• 25 Sohmiya M, Kato Y. Human growth hormone and insulin-like growth factor-I inhibit erythropoietin secretion from the kidney of adult rats.  J Endocrinology. 2005;  199-207
• 26 Spallone V, Maiello MR, Kurukulasuriya N. et al . Does autonomic neuropathy play a role in erythropoietin regulation on non-proteinuric Type 2 diabetic patients?.  Diab Medicine. 2004;  21 1174-1180
• 27 Thomas MC, Tsalamandris C, MacIsaac R. et al . Functional erythropoietin deficiency in patients with Type 2 diabetes and anaemia.  Diab Medicine. 2006;  23 502-509
• 28 Thomas MC, MacIsaac RJ, Tsalamandris C. et al . Unrecognized anaemia in patients with diabetes: a cross-sectional survey.  Diab Care. 2003;  26 1164-1169

Correspondence